<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-17_23-40-44</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Advanced epithelial adnexal malignancy with peritoneal and nodal disease on neoadjuvant platinum–taxane, but histologic subtype, response, and operability remain insufficiently characterized for definitive surgical versus systemic sequencing decisions.

Core Treatment Strategy:
- Do not commit today to interval debulking; await structured radiology response and resectability assessment integrating CT and PET findings (requested, pending).  
- Obtain urgent comprehensive preoperative assessment (ECOG, comorbidities, nutrition, anesthetic risk, chemo tolerance) to determine surgical fitness and perioperative risk.  
- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with germline and somatic profiling to plan maintenance.  
- Maintain platinum-taxane–based systemic strategy in principle, but adjust intensity and timing only after imaging, pathology, molecular, and fitness data are integrated.  

Change Triggers:
- If imaging shows substantial response and disease judged resectable with acceptable risk, shift toward interval debulking followed by systemic/maintenance therapy.  
- If imaging or fitness assessment indicates unresectable disease or prohibitive surgical risk, prioritize continued systemic therapy and defer debulking, reassessing periodically.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>盆腔肿块新辅2程，咨询手术；卵巢恶性肿瘤：盆腔肿物：2025.04.26 外院CT：双侧附件区占位（左侧59*74*92mm），左侧较大，考虑恶性；子宫左壁受侵待排，广泛腹膜种植转移，中量腹水，左侧髂血管旁、腹膜后、心膈角多发肿大淋巴结，考虑转移；子宫上壁稍低强化结节，转移瘤待排2025.04.27 CA125 823,CA153 294,CA724 62.7,CEA 0.8,NSE 19.7,CA199 10.6,HE4 480,AFP 2.43,SCCA 0.92025.04.28 外院超声下腹腔积液置管引流，盆腔占位穿刺活检：镜下形态符合恶性，考虑为分化差的癌，不排除高浆病理切片未带2025.04.29 外院PETCT：双侧附件区病灶代谢活跃，考虑恶性；左侧锁上、双侧内乳区、双侧肋膈角、腹腔、腹膜后、左侧髂血管旁多发淋巴结代谢活跃，考虑转移；腹盆腔腹膜多发病灶代谢活跃2025.04.30 外院肠镜：未见明显异常2025.04.30 外院胃镜：慢性非萎缩性胃炎常规报告（2025.05.07）：腹水冲洗液见肿瘤细胞， 倾向腺癌。建议行细胞块及免疫酶标检查帮助诊断。常规报告（2025.05.08）：腹水细胞块切片内见恶性肿瘤细胞，倾向腺癌。建议行免疫酶标检查帮助诊断。2025.05.09-2025.06.09 紫杉醇+卡铂新辅2程2025.06.30：CA19-9:17.50U/ml,CA125:75.00U/ml↑,AFP:2.53ng/ml,CEA:1.64ng/ml,HE4:126.00pmol/L↑,ROMA:44.54%(绝经前)↑,ROMA.:52.50%(绝经后)↑CT（2025.07.01）：腹膜及系膜多发强化小结节，请结合其他检查。肝胃间隙、腹膜后散在小淋巴结，请结合临床。肝囊肿，随访。胰头脂肪浸润可能，随访；胆囊结石。CT（2025.07.01）：腹膜及系膜稍浑浊增厚，伴多发强化小结节影，请结合临床。腹膜后散在小淋巴结，请随访。咨询手术治疗</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;2.53 ng/ml (latest 2025-06-30)&quot;,&quot;CA125&quot;:&quot;75.00 U/ml (latest 2025-06-30)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Consulted for surgery&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;Peritoneal seeding&quot;,&quot;Ascites&quot;,&quot;Lymph node metastases&quot;,&quot;Pelvic mass&quot;],&quot;histology&quot;:&quot;分化差的癌&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian malignant tumor&quot;,&quot;site&quot;:&quot;Pelvis / adnexa&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;2&quot;,&quot;end_date&quot;:&quot;2025-06-09&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;紫杉醇+卡铂&quot;,&quot;start_date&quot;:&quot;2025-05-09&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Yes&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2025-06-09&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;start_date&quot;:&quot;2025-05-09&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;Unknown&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;performed&quot;:&quot;Unknown&quot;,&quot;procedure&quot;:&quot;Unknown&quot;},&quot;VISIT_DATE&quot;:&quot;2025-07-01&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2025-06-09&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;823&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;75.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;75.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;480&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;126.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;126.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;10.6&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;17.50&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;17.50&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA153&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;294&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;294&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;},{&quot;analyte&quot;:&quot;CA724&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;62.7&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;62.7&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;},{&quot;analyte&quot;:&quot;CEA&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;0.8&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;1.64&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;1.64&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;NSE&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;19.7&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;19.7&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;2.43&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;2.53&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;2.53&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;SCCA&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;0.92&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;0.92&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;},{&quot;analyte&quot;:&quot;ROMA&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;44.54 (premenopausal)&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;52.50 (postmenopausal)&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;52.50 (postmenopausal) / 44.54 (premenopausal)&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;%&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2025-04-28&quot;,&quot;description&quot;:&quot;Biopsy with malignant morphology&quot;,&quot;type&quot;:&quot;Other&quot;},{&quot;date&quot;:&quot;2025-05-09&quot;,&quot;description&quot;:&quot;Start 紫杉醇+卡铂 (neoadjuvant)&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2025-06-09&quot;,&quot;description&quot;:&quot;Completed 2 cycles 紫杉醇+卡铂&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2025-04-29&quot;,&quot;description&quot;:&quot;FDG-PET/CT showing widespread avid disease&quot;,&quot;type&quot;:&quot;Imaging&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Completed 2 cycles of 紫杉醇+卡铂 (2025-05-09 to 2025-06-09)&quot;,&quot;last_admin_date&quot;:&quot;2025-06-09&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;紫杉醇+卡铂 (2025-05-09-2025-06-09)&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[{&quot;avid_lesions&quot;:[&quot;Bilateral adnexal lesions&quot;,&quot;Left supraclavicular and bilateral internal mammary nodes&quot;,&quot;Bilateral costophrenic angle nodes&quot;,&quot;Abdominal, retroperitoneal, left iliac vessel nodes&quot;,&quot;Multiple peritoneal and pelvic implants&quot;],&quot;confidence&quot;:&quot;High&quot;,&quot;date&quot;:&quot;2025-04-29&quot;,&quot;non_avid_notes&quot;:[],&quot;type&quot;:&quot;FDG-PET/CT&quot;}]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;Malignant cells&quot;,&quot;Poorly differentiated carcinoma (considered)&quot;],&quot;date&quot;:&quot;2025-04-28&quot;,&quot;diagnosis&quot;:&quot;镜下形态符合恶性，考虑为分化差的癌，不排除高浆病理切片未带&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Pelvic mass&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;镜下形态符合恶性，考虑为分化差的癌，不排除高浆病理切片未带&quot;,&quot;sample_type&quot;:&quot;Core biopsy&quot;,&quot;site&quot;:&quot;Pelvic mass (adnexal)&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[&quot;IHC not yet reported&quot;]},{&quot;components&quot;:[&quot;Tumor cells in ascites favor adenocarcinoma&quot;],&quot;date&quot;:&quot;2025-05-07&quot;,&quot;diagnosis&quot;:&quot;倾向腺癌&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Peritoneal cavity&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;腹水冲洗液见肿瘤细胞， 倾向腺癌。建议行细胞块及免疫酶标检查帮助诊断。&quot;,&quot;sample_type&quot;:&quot;Cytology (ascites)&quot;,&quot;site&quot;:&quot;Ascites&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Cell block and IHC recommended&quot;]},{&quot;components&quot;:[&quot;Malignant tumor cells, favors adenocarcinoma&quot;],&quot;date&quot;:&quot;2025-05-08&quot;,&quot;diagnosis&quot;:&quot;腹水细胞块切片内见恶性肿瘤细胞，倾向腺癌&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Peritoneal cavity&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;常规报告（2025.05.08）：腹水细胞块切片内见恶性肿瘤细胞，倾向腺癌。建议行免疫酶标检查帮助诊断。&quot;,&quot;sample_type&quot;:&quot;Cell block&quot;,&quot;site&quot;:&quot;Ascites cell block&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[&quot;IHC recommended&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Bilateral adnexa&quot;,&quot;Peritoneum&quot;,&quot;Uterus&quot;,&quot;Pelvis&quot;],&quot;date&quot;:&quot;2025-04-26&quot;,&quot;findings&quot;:[&quot;Bilateral adnexal masses (left 59x74x92 mm)&quot;,&quot;Extensive peritoneal implants&quot;,&quot;Moderate ascites&quot;,&quot;Multiple enlarged lymph nodes (left iliac vessel, retroperitoneal, cardiophrenic)&quot;],&quot;impression&quot;:&quot;Bilateral adnexal lesions suspicious for malignancy with peritoneal metastases and ascites&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Peritoneum&quot;,&quot;Mesentery&quot;,&quot;Liver-gastric space&quot;,&quot;Retroperitoneum&quot;],&quot;date&quot;:&quot;2025-07-01&quot;,&quot;findings&quot;:[&quot;Multiple small enhancing peritoneal and mesenteric nodules&quot;,&quot;Peritoneal/mesenteric slight hazy thickening&quot;,&quot;Scattered small retroperitoneal lymph nodes&quot;,&quot;Liver cysts&quot;,&quot;Cholelithiasis&quot;],&quot;impression&quot;:&quot;Peritoneal and mesenteric enhancing nodules consistent with peritoneal disease; retroperitoneal nodes; correlate clinically&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2025-04-26&quot;,&quot;description&quot;:&quot;External CT: bilateral adnexal masses (left 59x74x92 mm), extensive peritoneal implants, moderate ascites, multiple enlarged nodes suspicious for metastasis&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Bilateral adnexal masses; peritoneal metastases suspected&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2025-04-27&quot;,&quot;description&quot;:&quot;Tumor markers drawn&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 823; CA153 294; CA724 62.7; CEA 0.8; NSE 19.7; CA199 10.6; HE4 480; AFP 2.43; SCCA 0.92&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA153, CA724, CEA, NSE, CA199, HE4, AFP, SCCA&quot;},{&quot;date&quot;:&quot;2025-04-28&quot;,&quot;description&quot;:&quot;Ultrasound-guided paracentesis with drain and pelvic mass core biopsy&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Biopsy: morphology consistent with malignancy; considered poorly differentiated carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Paracentesis and biopsy&quot;},{&quot;date&quot;:&quot;2025-04-29&quot;,&quot;description&quot;:&quot;External PET/CT showed FDG-avid bilateral adnexal lesions, multiple FDG-avid lymph nodes and peritoneal implants&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Metastatic disease suspected&quot;,&quot;regimen_or_test&quot;:&quot;PET/CT&quot;},{&quot;date&quot;:&quot;2025-05-07&quot;,&quot;description&quot;:&quot;Ascites cytology: tumor cells present, favor adenocarcinoma; recommended cell block and IHC&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;Tumor cells present; favors adenocarcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Ascites cytology&quot;},{&quot;date&quot;:&quot;2025-05-09&quot;,&quot;description&quot;:&quot;Start chemotherapy: 紫杉醇+卡铂 neoadjuvant&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Planned 2 cycles (neoadjuvant)&quot;,&quot;regimen_or_test&quot;:&quot;紫杉醇+卡铂&quot;},{&quot;date&quot;:&quot;2025-06-09&quot;,&quot;description&quot;:&quot;Completed 2 cycles of 紫杉醇+卡铂&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;End of listed chemotherapy course&quot;,&quot;regimen_or_test&quot;:&quot;紫杉醇+卡铂&quot;},{&quot;date&quot;:&quot;2025-06-30&quot;,&quot;description&quot;:&quot;Repeat tumor markers&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 17.50 U/ml; CA125 75.00 U/ml↑; AFP 2.53 ng/ml; CEA 1.64 ng/ml; HE4 126.00 pmol/L↑; ROMA 44.54% (premenopausal)↑; ROMA 52.50% (postmenopausal)↑&quot;,&quot;regimen_or_test&quot;:&quot;CA19-9, CA125, AFP, CEA, HE4, ROMA&quot;},{&quot;date&quot;:&quot;2025-07-01&quot;,&quot;description&quot;:&quot;CT: multiple small enhancing peritoneal and mesenteric nodules, scanty peritoneal thickening, scattered small retroperitoneal nodes&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Peritoneal/mesenteric nodules; follow clinical correlation&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before deciding on interval debulking after only two neoadjuvant cycles, we need documented ECOG, comorbidities, organ function, and chemo tolerance, plus a clear statement of surgical fitness from anesthesia.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please provide a formal side‑by‑side response assessment comparing baseline CT/PET with 2025‑07‑01 CT, explicitly commenting on peritoneal disease burden, nodal status (including supraclavicular), and likelihood of achieving no gross residual disease.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>We urgently need IHC and a finalized report specifying histologic subtype, grade, and likely primary site from existing biopsy/ascites material to guide systemic and maintenance planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>If available, please comment on whether prior PET/CT suggests any sites that would predict unresectable residual disease despite aggressive cytoreduction, to inform timing and extent of surgery.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please provide a formal comparative report of baseline vs latest CT/PET, explicitly grading response and commenting on likelihood of complete/optimal cytoreduction, including extra-abdominal nodes.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>We need finalized histologic subtype, grade, and confirmed primary site with IHC as soon as possible to guide systemic and maintenance planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>chair</td><td>A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>radiologist</td><td>Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>chair</td><td>From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Advanced ovarian malignancy with peritoneal and nodal spread; partial biochemical response to two neoadjuvant platinum–taxane cycles.  \n- Before surgery decision, urgently need updated performance status, comorbidities, nutritional status, and anesthetic risk assessment.  \n- Require standardized radiology comparison (baseline vs 2025-07-01 CT and prior PET/CT) to quantify response and resectability.  \n- Pathology incomplete: need IHC, definitive histologic subtype, grade, and tumor origin confirmation; then order germline and somatic profiling (BRCA/HRD).  \n- MDT to decide: interval debulking feasibility vs further neoadjuvant therapy once operability, pathology, and genetics are clarified.&quot;,
  &quot;oncologist&quot;: &quot;- Advanced bilateral ovarian carcinoma with peritoneal, nodal, ascitic disease; currently post‑2 cycles neoadjuvant platinum‑taxane, evaluated for interval debulking.  \n\n- Tumor markers (CA125, HE4, ROMA) substantially decreased but still elevated, suggesting partial response; detailed radiologic response assessment missing, needs updated CT/MRI.  \n\n- Organ function, performance status, neuropathy, marrow and renal reserves are unknown/needs update to judge feasibility of continued platinum‑taxane and perioperative risk.  \n\n- Germline and somatic mutation status (BRCA, HRR genes, MSI, others) unknown/needs update to plan postoperative maintenance and future systemic options.  \n\n- Surgical team’s assessment of resectability and planned timing/extent of cytoreduction is unknown/needs update to coordinate systemic therapy sequencing.&quot;,
  &quot;radiologist&quot;: &quot;- CT shows multiple small enhancing peritoneal and mesenteric nodules, consistent with disseminated peritoneal disease.[@IMAGING_STUDIES|2025-07-01]\n\n- Scattered small retroperitoneal lymph nodes; size and progression versus prior unclear, recommend comparison with earlier imaging.[@IMAGING_STUDIES|2025-07-01]\n\n- Prior CT demonstrated large bilateral adnexal masses with extensive peritoneal implants, ascites, and nodal disease, suggesting advanced pelvic malignancy.[@IMAGING_STUDIES|2025-04-26]\n\n- PET/CT previously showed widespread FDG-avid pelvic, peritoneal, and nodal disease including supradiaphragmatic nodes, confirming systemic metastatic involvement.[@PET_IF_AVAILABLE|2025-04-29]\n\n- Trend of adnexal masses, ascites volume, and nodal size between April and July CTs is unknown; need formal side-by-side comparison.&quot;,
  &quot;pathologist&quot;: &quot;- Current material supports malignant epithelial tumor, favor adenocarcinoma, from pelvic/adnexal mass with malignant ascites cytology [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Tumor grade, exact subtype (e.g., high‑grade serous vs others), and primary site remain undetermined/uncertain [@HISTOLOGY_AND_IHC|2025-04-28].  \n- No immunohistochemistry yet on core biopsy or ascites cell block; IHC panel urgently needed for definitive classification [@HISTOLOGY_AND_IHC|2025-05-08].  \n- No molecular testing (HRD/BRCA, MSI, TMB, HER2, PD‑L1) reported; comprehensive predictive panel status unknown/needs update.  \n- Staging information (imaging, surgical findings, peritoneal/organ involvement extent) missing; pathologic stage cannot be assigned, needs radiology/surgical reports.&quot;,
  &quot;nuclear&quot;: &quot;- FDG-avid bilateral adnexal lesions with extensive peritoneal and pelvic implants indicate metabolically active adnexal primary with peritoneal carcinomatosis [@PET_CT|2025-04-29].  \n- FDG-avid retroperitoneal, left iliac, costophrenic, internal mammary, and left supraclavicular nodes suggest disseminated nodal metastases, upstaging beyond locoregional disease [@PET_CT|2025-04-29].  \n- PET/CT extends CT findings by confirming metabolic activity of peritoneal and nodal disease, strengthening suspicion for advanced-stage ovarian malignancy [@PET_CT|2025-04-29; @IMAGING_CONTEXT|2025-04-26].  \n- PET meaningfully changes staging by demonstrating extra-abdominal nodal involvement (internal mammary, supraclavicular), implying at least distant metastatic spread [@PET_CT|2025-04-29].  \n- For current visit, need histology, CA-125, prior treatments, and interval imaging to assess for recurrence vs. untreated advanced presentation (unknown/needs update).&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Defer interval debulking decision until standardized CT/PET response and resectability assessment is completed; request urgent integrated report (baseline vs 2025‑07‑01).  \n- Obtain full preoperative evaluation (performance, comorbidities, nutrition, organ function, neuropathy, anesthetic risk); surgery contingent on acceptable overall risk.  \n- Prioritize pathology work‑up: IHC, grade, and primary site assignment on core and cell‑block material; escalate if delayed.  \n- Initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, PD‑L1, HER2, others) once histologic subtype finalized.  \n- Reconvene MDT promptly with imaging, pathology, and risk data to choose between interval debulking versus additional/modified neoadjuvant and outline postoperative/maintenance strategy.&quot;,
    &quot;oncologist&quot;: &quot;- Defer decision on interval debulking versus further neoadjuvant therapy until standardized CT/PET response and resectability report is available (requested, pending).  \n\n- Urgently complete IHC on existing tissue to define subtype, grade, and primary site; initiate comprehensive germline and somatic profiling afterward.  \n\n- Arrange full preoperative assessment: performance status, comorbidities, nutritional/anesthetic risk, and detailed documentation of chemotherapy tolerance and neuropathy (currently unknown).  \n\n- Obtain up-to-date labs for marrow, renal, and hepatic function to confirm suitability for continued platinum-based therapy and potential surgery (unknown).  \n\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize timing of surgery and systemic/maintenance strategy.&quot;,
    &quot;radiologist&quot;: &quot;- Arrange formal side‑by‑side review of baseline vs 2025-07-01 CT, with PET correlation, to quantify disease burden and resectability.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01][@PET_IF_AVAILABLE|2025-04-29]\n\n- In the comparative report, separately characterize peritoneal/mesenteric implants (size, distribution, bowel/mesenteric involvement) relevant to optimal cytoreduction.[@IMAGING_STUDIES|2025-07-01]\n\n- Systematically assess nodal disease (pelvic, para‑aortic, cardiophrenic, supraclavicular) for size, conglomeration, and relationship to major vessels/structures.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\n\n- Comment explicitly on imaging features predicting unresectable disease (e.g., root-of-mesentery, porta hepatis, diffuse small‑bowel serosal involvement) if present/absent.[@IMAGING_STUDIES|2025-07-01]\n\n- Deliver structured radiology response/resectability report before MDT reconvening to inform timing and extent of interval debulking.[@IMAGING_STUDIES|2025-07-01]&quot;,
    &quot;pathologist&quot;: &quot;- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Expedite IHC on pelvic mass biopsy and ascites cell block to define subtype, grade, and likely primary site [@HISTOLOGY_AND_IHC|2025-05-08].  \n- Once histotype/grade established, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); currently unknown.  \n- Request finalized, structured CT±PET baseline-versus-2025-07-01 response and resectability report to align surgical planning with pathology; pending/unknown.  \n- Reconvene MDT after IHC, molecular profiling, and imaging response report are available to integrate definitive pathology into staging and future management discussions.&quot;,
    &quot;nuclear&quot;: &quot;- Maintain current plan to delay surgical decisions until formal CT/PET side‑by‑side response and resectability report is completed (requested, pending).  \n- Prioritize urgent IHC and full histologic characterization to define subtype, grade, and primary site (currently unknown, needs update).  \n- Complete germline and somatic profiling after histology finalization to inform future systemic and maintenance strategy (currently unknown, needs update).  \n- Obtain comprehensive preoperative, anesthetic, and organ‑function assessments to clarify surgical fitness and perioperative risk (currently unknown, needs update).  \n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking timing and goals.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Defer interval debulking decision until updated performance status, comorbidities, organ function, and chemo tolerance are documented (all currently unknown).  \n- Obtain standardized baseline vs 2025-07-01 CT comparison with PET correlation, explicitly grading peritoneal and nodal resectability (currently unknown).  \n- Expedite IHC on pelvic mass and ascites cell block to define epithelial subtype, grade, and likely primary site (unknown).  \n- Initiate germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1) once histology finalized; results will guide maintenance.  \n- Reconvene MDT promptly after imaging, pathology, and molecular updates to choose between interval debulking versus further neoadjuvant and to sequence subsequent systemic/maintenance therapy.&quot;,
    &quot;oncologist&quot;: &quot;- Defer decision on interval debulking versus further neoadjuvant therapy until structured CT/PET response and resectability report is available (currently unknown).  \n\n- Urgently obtain full preoperative assessment: ECOG status, comorbidities, nutrition, anesthetic risk, and detailed chemo tolerance/neuropathy documentation (unknown).  \n\n- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with comprehensive germline and somatic profiling (all unknown).  \n\n- Update labs for marrow, renal, and hepatic function to confirm suitability for ongoing platinum-based therapy and major surgery (values unknown).  \n\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize surgical timing and systemic/maintenance strategy.&quot;,
    &quot;radiologist&quot;: &quot;- Generate standardized side‑by‑side report comparing baseline 2025-04-26 CT and 2025-07-01 CT, quantifying measurable disease and response.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01]\n\n- Integrate 2025-04-29 PET/CT to map FDG‑avid peritoneal and nodal disease onto latest CT for operability assessment.[@PET_IF_AVAILABLE|2025-04-29][@IMAGING_STUDIES|2025-07-01]\n\n- Detail peritoneal carcinomatosis distribution, bowel/mesenteric involvement, and any imaging signs of likely unresectable disease on latest CT.[@IMAGING_STUDIES|2025-07-01]\n\n- Characterize nodal disease burden (pelvic, para‑aortic, cardiophrenic, supraclavicular) with size, conglomeration, and relation to major vessels.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\n\n- Deliver structured response/resectability report before MDT reconvening to guide interval debulking decisions versus further neoadjuvant therapy.[@IMAGING_STUDIES|2025-07-01]&quot;,
    &quot;pathologist&quot;: &quot;- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade still unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Urgently perform IHC on pelvic core biopsy and ascites cell block to define histologic subtype, grade, and likely primary [@HISTOLOGY_AND_IHC|2025-05-08].  \n- After histotype/grade clarification, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); all currently unknown.  \n- Ensure radiology delivers structured baseline-versus-2025-07-01 CT with PET correlation, including quantified response and detailed resectability assessment; currently missing/unknown.  \n- Reconvene MDT when IHC, molecular profile, and standardized imaging response/resectability report are available to integrate definitive pathology into staging decisions.&quot;,
    &quot;nuclear&quot;: &quot;- Maintain plan for urgent comprehensive preoperative and anesthetic assessment; performance status and operative risk remain unknown/needs update.  \n- Proceed with a structured baseline-versus-01‑07‑2025 CT report with PET correlation to quantify response and resectability (requested, unknown/needs update).  \n- Finalize histology with IHC to define subtype, grade, and primary site before definitive staging (currently unknown/needs update).  \n- After histology, complete germline and somatic profiling to inform future systemic and maintenance strategies (currently unknown/needs update).  \n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking versus further neoadjuvant therapy.&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>Presumed high-grade Müllerian adenocarcinoma, platinum-NA, with bilateral adnexal masses, diffuse peritoneal and nodal metastases; no BRCA/HRD/MSI/PD-L1 data; good response in CA125/HE4; no reported organ dysfunction or performance constraints—guidance on systemic therapy and surgery?</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.5612 nccn_ovariancancer_v3_2025__v00000000 [PAGE 11]
    Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Gui…
[2] score=0.5601 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 6]
    carcinoma demonstrated that adjuvant platinum-based ChT prolonged survival, but did not prospectively evaluate his- tological subtypes.38,39 High-grade EC has a similar prog- nosis to HGSC and is worse than low-grade EC. It is not clear whether there is any survival beneﬁt for adjuvant ChT in stage …
[3] score=0.5563 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15]
    Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Gui…
[4] score=0.5560 nccn_ovariancancer_v3_2025__v00000000 [PAGE 22]
    to anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is performed with gadolinium-based contrast agents (unless contraindicated due to anaphylaxis) and is preferred in select patients with renal dysfunction over CT. Chest CT can be done with or without iodinated IV c…
[5] score=0.5558 nccn_ovariancancer_v3_2025__v00000000 [PAGE 11]
    4. C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as indicated. x No definitive evidence of disease. Grade 2 endometrioid Grade 3 endometrioid/ high-grade serous carcinomat Platinum-based chemotherapy (see primary regimens for stage II–IV disease [OV-C, 6 of 12])n,v PRIMARY…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.5612170100212097,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-4\nPATHOLOGIC STAGINGt,u\nStage IA or IB\nStage lC\n(High-grade serous or\ngrade 2/3 endometrioid)\nStage II\nStage III\nStage IV\nIV platinum-based therapyn,v\n(see primary regimens for\nstage I disease [OV-C, 5 of 12])\nObserve\nor\nIntravenous (IV) platinum-based\ntherapyn,v (see primary regimens for\nstage I disease [OV-C, 5 of 12])\nMonitoring/\nFollow-up\n(OV-6)\nMaintenance\nTherapy (OV-5)\na CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.5601452589035034,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 6,
    &quot;text&quot;: &quot;carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneﬁt for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.5562877655029297,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-8\nDISEASE STATUSf,dd,ee\nPlatinum-\nsensitive\ndiseaseff:\nComplete\nremission and\nrelapse ≥6 mo\nafter completing\nprior\nchemotherapy\nRadiographic\nand/or clinical\nrelapse\nBiochemical\nrelapse (rising\nCA-125 and no\nradiographic\nevidence of\ndisease)\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\nj Principles of Surgery (OV-A).\nk Principles of Pathology (OV-B).\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.5560267567634583,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 22,
    &quot;text&quot;: &quot;to anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.\nChest CT can be done with or without iodinated IV contrast.\nq There are data regarding the utility of CA-125 for monitoring of ovarian cancer\nafter completion of primary therapy. See The Society of Gynecologic Oncology\n(SGO) position statement and Discussion.\nr See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk\nAssessment: Colorectal, Endometrial, and Gastric.\ns There is no standard sequencing of drugs for recurrent disease. Considerations\ninclude prior therapies, disease burden, relative efficacy, and relative toxicity\nprofile.\nt Consider secondary cytoreduction in patients with long disease-free interval,\nisolated masses rather than diffuse carcinomatosis on imaging, and/or bowel\nobstruction.\nu An aromatase inhibitor (ie, letrozole, anastrozole, exemestane) is preferred&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.5558041334152222,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;4. \u0007C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as\nindicated.\nx No definitive evidence of disease.\nGrade 2 endometrioid\nGrade 3 endometrioid/\nhigh-grade serous\ncarcinomat\nPlatinum-based\nchemotherapy\n(see primary\nregimens for stage\nII–IV disease [OV-C,\n6 of 12])n,v\nPRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPYv\nProvide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n• See NCCN Guidelines\nfor Palliative Care\n• See NCCN Guidelines\nfor Survivorship\n• Provide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n\u0017See NCCN Guidelines\nfor Palliative Care\n\u0017See NCCN Guidelines\nfor Survivorship\nLCOC-1\nLess common ovarian cancers (LCOC), any stageo,u\nComplete\nResponse\n(CR)x/Partial\nResponse (PR)\nStable disease\nor progression\nTherapy for Persistent\nDisease or Recurrence\n(OV-7)\nImaginga\nas clinically\nindicated:\neg, C/A/P CT, chest\nCT, A/P MRI, PET/\nMRI, PET/CT (skull\nbase to mid-thigh)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- NCCN 2025: For apparent stage I epithelial ovarian cancer, adjuvant platinum-based chemotherapy is recommended for grade 3 endometrioid and high-grade serous carcinomas; observation may be considered for lower-risk (eg, grade 1–2) endometrioid histology after comprehensive staging [nccn_ovariancancer_v3_2025__v00000000 p11, p15].  
- NCCN 2025: Primary systemic regimens for stage II–IV epithelial ovarian cancer are carboplatin plus paclitaxel (IV q3wk) or other platinum-taxane combinations; these regimens are also used as adjuvant therapy in higher-risk early-stage disease [nccn_ovariancancer_v3_2025__v00000000 p15].  
- ESGO/ESMO/ESP 2024: High‑grade endometrioid ovarian carcinoma has prognosis similar to high‑grade serous carcinoma and clearly worse than low‑grade endometrioid, supporting use of adjuvant platinum-based chemotherapy for high‑grade disease even in early stages [esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 p6].  
- ESGO/ESMO/ESP 2024: Evidence for survival benefit of adjuvant chemotherapy in stage I endometrioid carcinoma is uncertain overall, but high‑risk features (high grade, incomplete staging, or other adverse factors) favor recommending adjuvant platinum-based chemotherapy [esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 p6].  
- NCCN 2025: Imaging for staging or restaging should include contrast-enhanced CT or MRI of chest/abdomen/pelvis; PET/CT can be used as clinically indicated to clarify equivocal findings or suspected metastases [nccn_ovariancancer_v3_2025__v00000000 p11, p22].  
- NCCN 2025: In patients with contraindications to iodinated contrast or significant renal dysfunction, MRI with gadolinium (if not contraindicated) is preferred over CT; chest CT may be done with or without IV contrast depending on renal/allergy status [nccn_ovariancancer_v3_2025__v00000000 p22].  
- NCCN 2025: Post-treatment surveillance should use symptom review, physical examination, and CA‑125 (if initially elevated) at defined intervals; routine imaging is reserved for concerning symptoms, exam, or marker rise rather than done indiscriminately [nccn_ovariancancer_v3_2025__v00000000 p11, p15].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:13.162219&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2025-07-01 15:38:50.183000&quot;,
      &quot;meta_info&quot;: &quot;63212719700818194X&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:13.162622&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;5394a9a70135&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:13.405760&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 0,
      &quot;img_n&quot;: 0,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2025-07-02 15:38:50&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:13.460489&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:41.148370&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Presumed high-grade Müllerian adenocarcinoma, platinum-NA, with bilateral adnexal masses, diffuse peritoneal and nodal metastases; no BRCA/HRD/MSI/PD-L1 data; good response in CA125/HE4; no reported organ dysfunction or performance constraints—guidance on systemic therapy and surgery?&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:41.148376&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:37:52.471259&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:40:40.318828&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 1846
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:40:40.319615&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:40:44.854955&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1322
    }
  }
]</pre>
  </details>

</body>
</html>
